Insider Trading Alert - SUBK, PDCO And MNTA Traded By Insiders

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Yesterday, Dec. 1, 2014, 117 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $311.47 to $11,658,664.23.

Highlighted Stocks Traded by Insiders:

Suffolk Bancorp (SUBK) - FREE Research Report

Danowski James E, who is Director at Suffolk Bancorp, bought 51 shares at $21.04 on Dec. 1, 2014. Following this transaction, the Director owned 36,560 shares meaning that the stake was boosted by 0.14% with the 51-share transaction.

Goodale Edgar F, who is Director at Suffolk Bancorp, bought 275 shares at $21.04 on Dec. 1, 2014. Following this transaction, the Director owned 108,591 shares meaning that the stake was boosted by 0.25% with the 275-share transaction.

Filipo Frank D, who is EVP & Chief Operating Officer at Suffolk Bancorp, bought 16 shares at $21.04 on Dec. 1, 2014. Following this transaction, the EVP & Chief Operating Officer owned 9,122 shares meaning that the stake was boosted by 0.18% with the 16-share transaction.

Gaviola Joseph A, who is Director at Suffolk Bancorp, bought 15 shares at $21.04 on Dec. 1, 2014. Following this transaction, the Director owned 6,206 shares meaning that the stake was boosted by 0.24% with the 15-share transaction.

Whitehouse James R, who is Evp at Suffolk Bancorp, bought 104 shares at $20.83 on Dec. 1, 2014. Following this transaction, the Evp owned 3,965 shares meaning that the stake was boosted by 2.68% with the 104-share transaction.

The shares most recently traded at $20.45, down $0.38, or 1.86% since the insider transaction. Historical insider transactions for Suffolk Bancorp go as follows:

  • 4-Week # shares bought: 1,781
  • 12-Week # shares bought: 1,781
  • 24-Week # shares bought: 9,611

The average volume for Suffolk Bancorp has been 17,400 shares per day over the past 30 days. Suffolk Bancorp has a market cap of $250.7 million and is part of the financial sector and banking industry. Shares are up 3.32% year-to-date as of the close of trading on Friday.

Suffolk Bancorp operates as the holding company for Suffolk County National Bank that provides commercial and retail banking, and wealth management services primarily in Nassau and Suffolk counties, New York. The stock currently has a dividend yield of 1.12%. The company has a P/E ratio of 17.2. Currently, there are no analysts who rate Suffolk Bancorp a buy, no analysts rate it a sell, and 1 rates it a hold.

Exclusive Offer: Get the latest Stock Analysis on SUBK - FREE

TheStreet Quant Ratings rates Suffolk Bancorp as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, good cash flow from operations, expanding profit margins, increase in stock price during the past year and notable return on equity. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Suffolk Bancorp Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Patterson Companies (PDCO) - FREE Research Report

Henriques George L, who is President - Subsidiary at Patterson Companies, sold 8,000 shares at $48.20 on Dec. 1, 2014. Following this transaction, the President - Subsidiary owned 42,670 shares meaning that the stake was reduced by 15.79% with the 8,000-share transaction.

The shares most recently traded at $47.96, down $0.24, or 0.5% since the insider transaction. Historical insider transactions for Patterson Companies go as follows:

  • 4-Week # shares sold: 1,095
  • 12-Week # shares sold: 1,095
  • 24-Week # shares sold: 1,095

The average volume for Patterson Companies has been 734,900 shares per day over the past 30 days. Patterson Companies has a market cap of $5.0 billion and is part of the services sector and wholesale industry. Shares are up 16.94% year-to-date as of the close of trading on Friday.

Patterson Companies, Inc. distributes dental, veterinary, and rehabilitation supplies. The stock currently has a dividend yield of 1.67%. The company has a P/E ratio of 23.0. Currently, there are 2 analysts who rate Patterson Companies a buy, no analysts rate it a sell, and 9 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on PDCO - FREE

TheStreet Quant Ratings rates Patterson Companies as a buy. The company's strengths can be seen in multiple areas, such as its increase in net income, revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity and increase in stock price during the past year. We feel these strengths outweigh the fact that the company shows weak operating cash flow. Get the full Patterson Companies Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Momenta Pharmaceuticals (MNTA) - FREE Research Report

Shapiro Bennett M, who is Director at Momenta Pharmaceuticals, sold 1,897 shares at $12.00 on Dec. 1, 2014. Following this transaction, the Director owned 10,834 shares meaning that the stake was reduced by 14.9% with the 1,897-share transaction.

Bishop John E, who is Senior VP, Pharmaceutical Scie at Momenta Pharmaceuticals, sold 64 shares at $11.60 on Dec. 1, 2014. Following this transaction, the Senior VP, Pharmaceutical Scie owned 108,505 shares meaning that the stake was reduced by 0.06% with the 64-share transaction.

The shares most recently traded at $11.80, up $0.20, or 1.69% since the insider transaction. Historical insider transactions for Momenta Pharmaceuticals go as follows:

  • 4-Week # shares sold: 9,306
  • 12-Week # shares sold: 16,669
  • 24-Week # shares sold: 33,479

The average volume for Momenta Pharmaceuticals has been 472,300 shares per day over the past 30 days. Momenta Pharmaceuticals has a market cap of $624.9 million and is part of the health care sector and drugs industry. Shares are down 33.37% year-to-date as of the close of trading on Friday.

Momenta Pharmaceuticals, Inc., a biotechnology company, is engaged in the structural characterization, process engineering, and biologic systems analysis of complex molecules in the areas of complex generics, biosimilars, and novel drugs. Currently, there are 3 analysts who rate Momenta Pharmaceuticals a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on MNTA - FREE

TheStreet Quant Ratings rates Momenta Pharmaceuticals as a sell. The company's weaknesses can be seen in multiple areas, such as its deteriorating net income, disappointing return on equity, weak operating cash flow, generally disappointing historical performance in the stock itself and feeble growth in its earnings per share. Get the full Momenta Pharmaceuticals Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

null

More from Markets

Week Ahead: Wall Street Looks to Jobs Report as North Korea Meeting Less Certain

Week Ahead: Wall Street Looks to Jobs Report as North Korea Meeting Less Certain

Dow and S&P 500 Decline, Energy Shares Fall as U.S. Crude Oil Slides 4%

Dow and S&P 500 Decline, Energy Shares Fall as U.S. Crude Oil Slides 4%

Replay: Jim Cramer on the Markets, 10-Year Yield, Oil Prices and Foot Locker

Replay: Jim Cramer on the Markets, 10-Year Yield, Oil Prices and Foot Locker

Video: You Could Live in a Ritz-Carlton or St. Regis Home

Video: You Could Live in a Ritz-Carlton or St. Regis Home

Component Stocks Rise After Trump Reverses Decision on ZTE

Component Stocks Rise After Trump Reverses Decision on ZTE